BioSpace News Archive

Xenetic Biosciences, Inc. today reported its financial results for the full year 2022 and provided a business update.

Evaxion Biotech A/S today announces that it has developed a new proprietary AI platform technology ObsERV™ to identify a new source of targets for personalized cancer therapy, potentially enabling treatment of patients that are currently considered unresponsive to cancer immunotherapy.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 30, 2023, to review its financial results for the year ended December 31, 2022 and to provide a Company update.

Valitor, a biotechnology company engineering better medicines to conquer drug limitations, announced that two abstracts have been accepted for poster presentation at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting taking place April 23-27, 2023 in New Orleans, LA.

Landos Biopharma, Inc. today provided a business update and announced financial results for the fourth quarter and full year ended December 31, 2022.

Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”) today announced that NXC-201 treatment continues to demonstrate 100% complete hematologic responses and 100% organ response rate.

Biomea Fusion, Inc. today announced that it will host a conference call and webcast to discuss the initial clinical data from the first two cohorts of the Phase II portion of COVALENT-111 on Tuesday, March 28th at 8:30 am ET.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces results from new scientific research that shows its COBLATION Intracapsular Tonsillectomy (CIT) technique can lead to improved post-operative outcomes in patients versus total tonsillectomy techniques.

AnPac Bio-Medical Science Co., Ltd. announced that on March 22, 2023, the Company has been notified by the Nasdaq Hearings Panel (“Panel”) of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s request for continued listing on The Capital Market has been granted.

JanOne today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 361,000 shares of the Company’s common stock at a purchase price of $1.